Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from GH Research ( (GHRS) ) is now available.
On July 23, 2025, GH Research PLC announced updates on its global pivotal program plans and development progress. The company reported a 73% remission rate in its Phase 2b trial for treatment-resistant depression with its GH001 product, showing significant efficacy and safety. The FDA has responded to GH Research’s IND application for GH001, with one remaining issue to address. The company plans to initiate its global pivotal program in 2026, aiming to revolutionize TRD treatment.
The most recent analyst rating on (GHRS) stock is a Buy with a $31.00 price target. To see the full list of analyst forecasts on GH Research stock, see the GHRS Stock Forecast page.
Spark’s Take on GHRS Stock
According to Spark, TipRanks’ AI Analyst, GHRS is a Neutral.
GH Research’s stock score reflects significant challenges in financial performance, with consistent losses and negative cash flows. The company’s strong equity base and low debt provide some stability. Technical indicators show some short-term momentum, but valuation concerns persist due to the negative P/E ratio and lack of profitability.
To see Spark’s full report on GHRS stock, click here.
More about GH Research
GH Research PLC is a clinical-stage biopharmaceutical company focused on developing transformative treatments for depression, specifically targeting treatment-resistant depression (TRD) with novel mebufotenin therapies.
Average Trading Volume: 179,619
Technical Sentiment Signal: Buy
Current Market Cap: $1.04B
See more insights into GHRS stock on TipRanks’ Stock Analysis page.